Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial

Blood (2024) 144 (Supplement 1): 3207.

https://doi.org/10.1182/blood-2024-208432

Published: 2024

Journal Articles

Integration of Geriatric Assessment and Genetic Profile Facilitates Personalized Treatment Selection and Follow-up in Old Patients with Newly Diagnosed Acute Myeloid Leukemia

Pilar Lancho Lavilla, Miguel Lopez-Esteban, Javier Ortiz-Alonso, Gracia Fajardo-Tórtola, Patricia Font Lopez, Marina Gomez Llobell, Jose Antonio Serra Resach, Ana Perez-Corral, Isabel Regalado Artamendi, Mónica Ballesteros Andrés, Carolina Martinez-Laperche, Gloria Figaredo Garcia-Mina, Raquel Fernández González, Carlos Jiménez, Diego Conde Royo, Cristina Pascual Izquierdo, María Teresa Vidán, Ramon García-Sanz, Gabriela Rodriguez Macias

Blood (2024) 144 (Supplement 1): 5050.

https://doi.org/10.1182/blood-2024-203872

Published: 2024

Journal Articles

Patients with Acute Myeloid Leukemia on Non-Intensive Therapy: Applicability of the European Leukemia Net Risk Classification

Pablo Silva, Jon Badiola, Reyes María Martín-Rojas, Ignacio Gómez-Centurión, Gabriela Rodríguez-Macias, Marina Gómez-Llobell, Carolina Martínez-Laperche, Diego Carbonell, Mónica Ballesteros, Ana Pérez-Corral, María Chicano, Patricia Font Lopez, Isabel Pérez-Sánchez, Ismael Buño, Javier Anguita, Mi Kwon, José Luis Díez-Martín

Blood (2021) 138 (Supplement 1): 3382.

https://doi.org/10.1182/blood-2021-153202

Published: 2021

Journal Articles

On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

Blood (2021) 138 (Supplement 1): 2598.

https://doi.org/10.1182/blood-2021-148876

Published: 2021

Journal Articles

Interobserver Variability with the Diagnosis of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) ¿Is the Threshold of 20% Bone Marrow Blasts Reproducible?

Blood (2021) 138 (Supplement 1): 2607.

https://doi.org/10.1182/blood-2021-149147

Published: 2021

Journal Articles

Day 14 Measurable Residual Disease As a Predictor of Post-Induction Response in Patients with Acute Myeloid Leukemia

Reyes María Martín-Rojas, Jon Badiola, Pablo Silva De Tena, Ana Pérez-Corral, Ignacio Gómez-Centurión, Gabriela Rodríguez-Macias, Mónica Ballesteros, Carolina Martínez-Laperche, Patricia Font Lopez, Isabel Pérez-Sánchez, Ismael Buño, Javier Anguita, Mi Kwon, Jose L. Diez-Martin

Blood (2021) 138 (Supplement 1): 1287.

https://doi.org/10.1182/blood-2021-150808

Published: 2021

Journal Articles

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-138810

Published: 2020

Journal Articles

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2019) 134 (Supplement_1): 673.

https://doi.org/10.1182/blood-2019-123854

Published: 2019

Journal Articles

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2019) 134 (Supplement_1): 4248.

https://doi.org/10.1182/blood-2019-127435

Published: 2019

Journal Articles

Percentage of Erythroid Cells in Bone Marrow at Diagnosis As a New Prognostic Factor in Patients with Myelodysplastic Syndrome

Blood (2018) 132 (Supplement 1): 4363.

https://doi.org/10.1182/blood-2018-99-110210

Published: 2018

Journal Articles

Hepcidin and Erythroferrone in the Anemia of Low-Risk Myelodysplastic Syndromes

Gillen Oarbeascoa, MD, Sara Redondo, MD, Maria Jose Morán-Jiménez, MD, Amalia Domingo, MD, Cristina Muñoz-Linares, MD, Maria Isabel Moreno-Carralero, MD, Jose Maria Bellon, Juan Francisco del Campo Rincon, MD, Jose Luis Díez-Martín, MD PhD, Patricia Font, MD

Blood (2018) 132 (Supplement 1): 3085.

https://doi.org/10.1182/blood-2018-99-116992

Published: 2018

Journal Articles

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

David P. Steensma, Uwe Platzbecker, Koen Van Eygen, Azra Raza, MD, Valeria Santini, Ulrich Germing, MD, Patricia Font, MD, Irina Samarina, MD, Maria Díez-Campelo, Sylvain Thepot, MD, Edo Vellenga, Mrinal M. Patnaik, MDMBBS, Jun Ho Jang, MD PhD, Jacqueline Bussolari, PhD, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Pierre Fenaux

Blood (2018) 132 (Supplement 1): 463.

https://doi.org/10.1182/blood-2018-99-114877

Published: 2018

Journal Articles

Interlaboratory Variation in CD34+ Cell Quantification in Low Risk Myelodysplastic Syndromes

Patricia Font, Dolores Subira, Sergio Matarraz, Celina Benavente, Teresa Cedena, Marta Morado, Ana Perez Corral, Jose Maria Bellon, Jose Luis Diez-Martin

Blood (2015) 126 (23): 5249.

https://doi.org/10.1182/blood.V126.23.5249.5249

Published: 2015

Journal Articles

A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD

María Díez Campelo, MD PhD, Julio Davila, MD, Sanchez Barba Mercedes, MD, Maria Lopez-Pavia, MD, Esperanza Such, PhD, Teresa Bernal, MD, Elisa Luño, Fernando Ramos, Marisa Calabuig, MD, Helena Pomares, MD, Bernardo Gonzalez, Brayan Merchan, MD, Edgardo Barranco, MD, Reyes Sancho Tello, Marta Callejas, Maria Jose Requena, María José Jiménez, Maria Pedreño, Angeles Medina, MD, Ana I Vicente, PhD, Andrea Campeny, Montse Cortes Sansa, Carmen Pedro, MD, Jose Falantes, MD, Maria Jesus Arilla, Abelardo Bárez, MD, Regina Garcia, MD, Maria Jose Arcos, Valle Gomez, Carolina Muñoz, Carlos Cervero, MD, Javier Casaño, Raquel De Paz, Luz Amigo, Andres Insunza, Juan Antonio Muñoz, Maria Teresa Cedena, Marta Gomez, Patricia Font, Raquel Del Campo, Carlos Fernandez Lago, Jose Antonio Gonzalez Hurtado, Maria Dolores Linares Latorre, Asuncion Mora Casado, Maria Vahi, MD PhD, Luis Benlloch, Guillermo Sanz, MD PhD, María Consuelo Cañizo, MD PhD

Blood (2015) 126 (23): 2896.

https://doi.org/10.1182/blood.V126.23.2896.2896

Published: 2015

Journal Articles

Azacitidine in Older Patients with Acute Myeloid Leukemia (AML) and Adverse Karyotype. Subanalisis from the Alma Study

Jose Falantes, MD, Guillermo Deben, MD, Violeta Martinez Robles, Joan Bargay, MD, Olga Salamero, MD, Carmen Pedro, MD, Santiago Redondo, Ana Garrido, MD, Juan Miguel Bergua, Mar Tormo, MD, Blanca Xicoy, MD PhD, Patricia Font, Tomás José González-López, MDPhD, Fernando Ramos, MDPhDMPH

Blood (2014) 124 (21): 945.

https://doi.org/10.1182/blood.V124.21.945.945

Published: 2014

Journal Articles

Inter-Observer Discordance With The Diagnosis Of Myelodysplastic Syndromes With Less Than 5% Bone Marrow Blasts: Unilineage Vs Multilineage Dysplasia and Reproducibility Of The Threshold Of 2% Blasts

Patricia Font, Javier Loscertales, Carlos Soto, Pilar Ricard, Carolina Muñoz Novas, Estela Martin-Clavero, Montserrat Lopez-Rubio, Luis Garcia-Alonso, Marta Callejas, Alfredo Bermejo, Celina Benavente, Monica Ballesteros, Teresa Cedena, María Calbacho, Raquel Urbina, Jesus Villarrubia, Ana Villegas

Blood (2013) 122 (21): 2768.

https://doi.org/10.1182/blood.V122.21.2768.2768

Published: 2013

Journal Articles

The Challenge Of Quantifying CD34+ Myeloid Cells In Myelodysplastic Syndromes With Less Than 5% Bone Marrow Blasts. Reproducibility Among 6 Flow Cytometry Observers

Patricia Font, Dolores Subirá, PhD, Sergio Matarraz, PhD, Celina Benavente, Teresa Cedena, Marta Morado, MD, Ana Pérez-Corral, MD, Jose Maria Bellon, Christian Gil Borrelli, Jose Luis Diez-Martin, MD, PhD

Blood (2013) 122 (21): 2769.

https://doi.org/10.1182/blood.V122.21.2769.2769

Published: 2013

Journal Articles

Azacitidine As Front-Line Therapy in AML: Results From Spanish National Registry. Alma Study Investigators

Blood (2012) 120 (21): 3593.

https://doi.org/10.1182/blood.V120.21.3593.3593

Published: 2012

Journal Articles

Role of BCL2 and MYC Alterations in Patients with Diffuse Large B-Cell Lymphoma

Leyre Bento, Carolina Martinez-Laperche, Víctor Noriega, Mi Kwon, Patricia Font, Santiago Osorio, Javier Menárguez, Ismael Buno, Jose Luis Diez Martin

Blood (2011) 118 (21): 5218.

https://doi.org/10.1182/blood.V118.21.5218.5218

Published: 2011

Journal Articles

Impact of Comorbidities In Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA)

Patricia Font, PhD, Valle Gomez Garcia De Soria, PhD, Javier Loscertales, PhD, Julio Garcia Suarez, PhD, Marta Callejas, PhD, Carmen Burgaleta, PhD, Santiago Osorio, PhD, Carlos Soto, PhD, Lucia Villalon, PhD, Jose Diez-Martin, Ana Villegas, PhD

Blood (2010) 116 (21): 4973.

https://doi.org/10.1182/blood.V116.21.4973.4973

Published: 2010

NARROW

Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial

Integration of Geriatric Assessment and Genetic Profile Facilitates Personalized Treatment Selection and Follow-up in Old Patients with Newly Diagnosed Acute Myeloid Leukemia

Patients with Acute Myeloid Leukemia on Non-Intensive Therapy: Applicability of the European Leukemia Net Risk Classification

On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

Interobserver Variability with the Diagnosis of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) ¿Is the Threshold of 20% Bone Marrow Blasts Reproducible?

Day 14 Measurable Residual Disease As a Predictor of Post-Induction Response in Patients with Acute Myeloid Leukemia

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Percentage of Erythroid Cells in Bone Marrow at Diagnosis As a New Prognostic Factor in Patients with Myelodysplastic Syndrome

Hepcidin and Erythroferrone in the Anemia of Low-Risk Myelodysplastic Syndromes

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

Interlaboratory Variation in CD34+ Cell Quantification in Low Risk Myelodysplastic Syndromes

A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD

Azacitidine in Older Patients with Acute Myeloid Leukemia (AML) and Adverse Karyotype. Subanalisis from the Alma Study

Inter-Observer Discordance With The Diagnosis Of Myelodysplastic Syndromes With Less Than 5% Bone Marrow Blasts: Unilineage Vs Multilineage Dysplasia and Reproducibility Of The Threshold Of 2% Blasts

The Challenge Of Quantifying CD34+ Myeloid Cells In Myelodysplastic Syndromes With Less Than 5% Bone Marrow Blasts. Reproducibility Among 6 Flow Cytometry Observers

Azacitidine As Front-Line Therapy in AML: Results From Spanish National Registry. Alma Study Investigators

Role of BCL2 and MYC Alterations in Patients with Diffuse Large B-Cell Lymphoma

Impact of Comorbidities In Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only